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Background: Nectin-2 is a Ca2+-independent cell-cell adhesion molecule that is one of the plasma membrane
components of adherens junctions. However, little has been reported about the involvement of Nectin-2 in cancer.
Methods: To determine the expression of Nectin-2 in cancer tissues and cancer cell lines, we performed gene
expression profile analysis, immunohistochemistry studies, and flow cytometry analysis. We also investigated the
potential of this molecule as a target for antibody therapeutics to treat cancers by generating and characterizing an
anti-Nectin-2 rabbit polyclonal antibody (poAb) and 256 fully human anti-Nectin-2 monoclonal antibodies (mAbs).
In addition, we tested anti-Nectin-2 mAbs in several in vivo tumor growth inhibition models to investigate the primary
mechanisms of action of the mAbs.
Results: In the present study, we found that Nectin-2 was over-expressed in clinical breast and ovarian cancer tissues
by using gene expression profile analysis and immunohistochemistry studies. Nectin-2 was over-expressed in various
cancer cell lines as well. Furthermore, the polyclonal antibody specific to Nectin-2 suppressed the in vitro proliferation
of OV-90 ovarian cancer cells, which express endogenous Nectin-2 on the cell surface. The anti-Nectin-2 mAbs we
generated were classified into 7 epitope bins. The anti-Nectin-2 mAbs demonstrated antibody-dependent cellular
cytotoxicity (ADCC) and epitope bin-dependent features such as the inhibition of Nectin-2-Nectin-2 interaction,
Nectin-2-Nectin-3 interaction, and in vitro cancer cell proliferation. A representative anti-Nectin-2 mAb in epitope bin
VII, Y-443, showed anti-tumor effects against OV-90 cells and MDA-MB-231 breast cancer cells in mouse therapeutic
models, and its main mechanism of action appeared to be ADCC.
Conclusions: We observed the over-expression of Nectin-2 in breast and ovarian cancers and anti-tumor activity of
anti-Nectin-2 mAbs via strong ADCC. These findings suggest that Nectin-2 is a potential target for antibody therapy
against breast and ovarian cancers.
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Nectins are Ca2+-independent cell adhesion molecules
that consist of 4 members: Nectin-1, Nectin-2, Nectin-3,
and Nectin-4. Each member of the Nectin family except
for Nectin-4 has 2 or 3 splicing variants [1]. All members
except for a secreted protein Nectin-1γ have an extracellu-
lar region that contains 3 immunoglobulin (Ig)-like do-
mains, a transmembrane region, and a cytoplasmic region.
Nectins form homo-cis-dimers on the cell surface via their* Correspondence: tomofumi.kurokawa@takeda.com
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reproduction in any medium, provided the orIg2-domain [2]. The cis-dimers further form homo- and
hetero-trans-dimers with other cis-dimers of Nectins on
adjacent cells via the Ig1-domain [2-8].
Nectin-2 has been reported to regulate cell adhesion
between epithelial cells through the formation of trans-
dimers between adjacent cells [1]. Nectin-2-mediated
cell adhesion induces the formation of E-cadherin-based
adherens junctions followed by the formation of claudin-
based tight junctions [9-12]. In addition to its function as
a cell adhesion molecule, previous studies have suggested
that Nectin-2 acts as an organizer of Sertoli cell-spermatid
junctions in the testis [13] and of synapse formation by
neurons [14,15] and as an entry receptor for viruses [16].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and


















































Figure 1 Over-expression of Nectin-2 mRNA in cancer tissues. A
box and whisker plot of the expression level of Nectin-2 mRNA in
normal tissues and cancer tissues. The vertical axis represents Nectin-
2 mRNA expression level. Nectin-2 mRNA expression in the indicated
tissues was analyzed using Affymetrix U_133 arrays as described in
Methods. The whiskers indicate the minimum and maximum values.
The box indicates the 25th–75th percentile. N, normal tissues; C,
cancer tissues. ***, p < 0.0001; **, p < 0.01; *, p < 0.05 as determined
by the Mann Whitney test.
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DNAM-1 and TIGIT [17-20]. Although anti-Nectin-2
antibodies have been examined from a functional perspec-
tive, such as for the inhibition of Nectin-2 binding to
DNAM-1, in vitro cell aggregation, or HSV-1 virion-
induced cell fusion into host cells [6,18,21,22], there has
been no report showing an anti-tumor effect of anti-
Nectin-2 antibody. In the present study, we show that
Nectin-2 is over-expressed in various cancers and that
anti-Nectin-2 mAb can exert an in vivo anti-tumor effect
on breast and ovarian cancer cells, which suggests the
potential of Nectin-2 as a target for antibody therapy for
cancer treatment.
Results
Over-expression of Nectin-2 in breast and ovarian cancers
With the aim of identifying target proteins for antibody
therapeutics, we searched for membrane-bound proteins
that were over-expressed in cancer tissues compared to
normal tissues using Affymetrix GeneChip Technology
and found that Nectin-2 mRNA was over-expressed in
various cancer tissues. An analysis that compared the
mean intensity in each tissue set demonstrated that
Nectin-2 was especially over-expressed in breast, ovar-
ian, and prostate cancer tissues (Figure 1). We subse-
quently confirmed the over-expression of Nectin-2
protein in breast and ovarian cancer tissues by immuno-
histochemistry (IHC) and found that Nectin-2 protein
was abundantly present in these cancer tissues while it
was undetectable in normal breast and ovary tissues
(Figure 2). A more extensive IHC study indicated that
Nectin-2 protein was over-expressed in more than 80%
of breast cancer tissue samples and approximately 50%
of ovarian cancer tissues samples (Table 1). In contrast,
Nectin-2 was expressed only in the liver and testis
within normal tissue specimens (Table 2). In a supple-
mental experiment, we observed Nectin-2-expression in
blood vessels (data not shown). Furthermore, Nectin-2
was broadly over-expressed in various breast and ovarian
cancer cell lines when its expression was tested by flow
cytometry (FCM) analysis using anti-Nectin-2 poAb
(Figure 3). For the evaluation of anti-Nectin-2 anti-
bodies in in vitro assays and in vivo studies, we selected
OV-90 ovarian cancer cells, which highly expressed
Nectin-2 with a median fluorescent intensity (MFI) of
242 in FCM, and MDA-MB-231 breast cancer cells
(MFI = 181).
Effect of anti-Nectin-2 poAb on OV-90 cancer cell
proliferation
Although we found that Nectin-2 was over-expressed in
various types of cancers, there has been no report
suggesting the involvement of Nectin-2 in cancer cell
proliferation. In order to investigate the potential ofNectin-2 as a target for antibody therapies of cancers,
we generated anti-Nectin-2 rabbit poAb using recom-
binant Nectin-2 protein as an immunogen. The anti-
Nectin-2 poAb at 30 μg/mL inhibited the proliferation
of OV-90 ovarian cancer cells by 10–15% (Figure 4). Al-
though the percentage of cancer cell growth inhibition
was insignificant, the suppression was reproducible.
Therefore, we decided to generate anti-Nectin-2 mAbs
to further evaluate the potential of antibody therapy to
treat Nectin-2 over-expressing cancers.
Generation of fully human anti-Nectin-2 mAbs
We generated fully human anti-Nectin-2 mAbs by
conventional hybridoma technology using KM mice that
carried the complete locus for the human immuno-
globulin heavy chain and a transgene for the human
immunoglobulin kappa light chain [23]. We immunized
the KM mice with a recombinant protein of the Nectin-
2 extracellular domain and/or recombinant Nectin-2
over-expressing cells. As a result of the immunization
and screening by a cell enzyme-linked immunosorbent
assay (ELISA) using Nectin-2/CHO cells, 256 hybridoma







Figure 2 Over-expression of Nectin-2 protein in breast and ovarian cancer tissues. Paraffin-embedded tissue sections were stained with
anti-Nectin-2 poAb as described in Methods. A, Normal breast tissue, B–D, breast infiltrating ductal carcinoma tissues. E, normal ovarian tissue,
and F–H, ovarian serous carcinoma tissues.
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scale culture of the hybridomas and were used for
characterization.
We selected 185 out of 256 mAbs that showed rela-
tively higher binding affinity to Nectin-2/CHO cells in
the cell ELISA for an epitope binning analysis. Binding
of biotinylated anti-Nectin-2 mAbs to the recombinant
CHO cells that over-expressed Nectin-2 was measured
in the absence and presence of an excess amount of
unlabeled anti-Nectin-2 mAbs. Based on the percentage
of competitive binding inhibition for each combination ofTable 1 Over-expression of Nectin-2 protein in breast and
ovarian cancer tissues (IHC)
Breast cancer tissue Ovarian cancer tissue




16/18 Serous carcinoma 22/40
Ductal carcinoma 7/7 Granular carcinoma 3/3
Infiltrating lobular
carcinoma








5/7 Mucinous carcinoma 1/4
Paget’s disease 7/7 Brenner tumor 1/1
positive/total Germinoma 0/4
Theca cell carcinoma 1/1
Metastasis carcinoma 1/6
positive/totalantibodies, we classified the mAbs into 7 major bins (I to
VII) by a clustering analysis method using Spotfire
DecisionSite for Lead Discovery (Figure 5).
Inhibitory activities of anti-Nectin-2 mAbs on the in vitro
proliferation of OV-90 cancer cells
As described above, anti-Nectin-2 rabbit poAb moder-
ately suppressed the in vitro proliferation of OV-90 ovar-
ian cancer cells. We next screened the 256 anti-Nectin-2
mAbs in the cell proliferation assay. The 30 mAbs that
showed certain growth inhibition activities against OV-
90 cells in the first screening were retested in the sameTable 2 Expression of Nectin-2 protein in normal tissues
(IHC)
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Figure 3 Over-expression of Nectin-2 in cancer cell lines. Expression levels of Nectin-2 in various human cancer cell lines were examined by
flow cytometry analysis using anti-Nectin-2 rabbit poAb. The vertical axis represents Nectin-2 protein expression level indicated as an MFI of FCM
analysis. MFI, median fluorescent intensity.
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http://www.molecular-cancer.com/content/12/1/60assay and 8 of them reproducibly inhibited cell prolifera-
tion (Figure 4). All 8 clones (Y-052, Y-047, Y-125, Y-137,
Y-187, Y-205, Y-214, and Y-226) inhibited OV-90 cell
proliferation in a concentration-dependent manner. All
of these mAbs except Y-052 belonged to epitope bin VI
(Figure 4). The concentration-dependent inhibitory
activity of the representative mAb Y-187 on OV-90 cell
proliferation is shown in Figure 6 as an example.Inhibitory activity of anti-Nectin-2 mAbs on Nectin-2-
Nectin-2 or Nectin-2-Nectin-3 interaction
As a cell adhesion molecule, Nectin-2 forms a cis-dimer
and then interacts with another Nectin-2-cis-dimer or
Nectin-3-cis-dimer on adjacent cells to form a homo-
trans-dimer or hetero-trans-dimer, respectively [2-8].
Previous reports showed that some anti-Nectin-2 anti-
bodies inhibited cell aggregation [6,21]. However, there
has been no report that measured the effect of anti-
Nectin-2 antibody separately on Nectin-2-Nectin-2 and
on Nectin-2-Nectin-3 trans-binding. We therefore ex-
amined whether anti-Nectin-2 mAbs could inhibit
Nectin-2-Nectin-2 or Nectin-2-Nectin-3 interaction
using ELISA-based or Biacore-based assays, respectively.
As summarized in Figure 7, most of the mAbs in epitope
bins V and VI inhibited both Nectin-2-Nectin-2 and
Nectin-2-Nectin-3 interactions. Interestingly, the mAb
in epitope bin V inhibited Nectin-2-Nectin-2 interaction
more strongly than the mAbs in epitope bin VI. In con-
trast, the mAbs in epitope bin VI, except Y-232,
inhibited Nectin-2-Nectin-3 interaction more strongly
than the mAbs in epitope bin V. The anti-Nectin-2
mAbs in epitope bins I and IV weakly inhibited inter-
action and the mAbs in epitope bin VII showed no in-
hibition of Nectin-2-Nectin-2 or Nectin-2-Nectin-3
interaction. Thus, the inhibitory activities of anti-Nectin-2
mAbs on Nectin-2-Nectin-2 and Nectin-2-Nectin-3
interactions were epitope bin-dependent.ADCC of anti-Nectin-2 mAbs on OV-90 cancer cells
ADCC is one mechanism of action of marketed thera-
peutic antibodies such as rituximab and trastuzumab
[24]. Among human IgG isoforms, IgG1 antibodies dem-
onstrate the most potent ADCC [25]. In order to evalu-
ate the epitope bin-dependency of anti-Nectin-2 mAbs
for ADCC, we selected a few IgG1 antibodies with simi-
lar antigen-binding affinity (EC50 in cell ELISA ranging
from 0.22 to 0.59 nM with the exception of Y-278 whose
EC50 was 2.1 nM) from each epitope bin and measured
the ADCC against OV-90 cells. Although the specific
cell lysis was saturated at around 25%, all of the anti-
Nectin-2 mAbs tested showed ADCC against OV-90
cells in a concentration-dependent manner. As shown in
Figure 8, the concentrations of antibody giving 15% spe-
cific cell lysis varied roughly from 0.01 to 1 μg/mL, even
though these mAbs showed similar binding affinities to
Nectin-2. Interestingly, all 3 anti-Nectin-2 mAbs in epi-
tope bin VII (Y-055, Y-414, and Y-443) appeared to show
the highest potency out of all the mAbs (Figure 8).Anti-tumor effect of anti-Nectin-2 mAbs against OV-90
cancer cells in a mouse subcutaneous xenograft model
To see if the anti-Nectin-2 mAbs exerted in vivo anti-
tumor effects, we selected 2 representative mAbs, Y-187
from epitope bin VI and Y-443 from epitope bin VII,
which showed different biological activities. Namely, Y-
187 inhibited Nectin-2-Nectin-3 interaction and in vitro
OV-90 cell proliferation and showed ADCC against OV-
90 cells (Figures 4, 6, 7, and 8), while Y-443 did not
inhibit Nectin-2-Nectin-2 or Nectin-2-Nectin-3 inter-
action or in vitro OV-90 cell proliferation, but did show
ADCC (Figures 4, 7, and 8). In a subcutaneous mouse
xenograft preventive model, intravenous administrations
of both Y-187 and Y-443 (15 mg/kg twice a week)
remarkably inhibited OV-90 tumor growth by 93% and



































































































































Figure 4 Inhibitory activity of anti-Nectin-2 mAbs on the proliferation of OV-90 cells. OV-90 cells were cultured in the presence of 30 μg/mL
anti-Nectin-2 mAbs and poAb with 1% FBS for 6 days. The percentage inhibition of cell proliferation on the vertical axis is the mean ± S.D. of triplicate
assays. *; antibodies that showed negative values for cell growth inhibition. #; antibodies that showed reproducible cell growth inhibition.
NA; not assigned.
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http://www.molecular-cancer.com/content/12/1/60Anti-tumor effect of Y-443 against MDA-MB-231 breast
cancer cells in a mouse lung metastasis model
Since the inhibition of the Nectin-2 function as a cell
adhesion molecule may cause adverse effects, we focused
on Y-443, which did not inhibit Nectin-2-Nectin-2 or
Nectin-2-Nectin-3 interaction (Figure 7), and further
evaluated its anti-tumor effect on MDA-MB-231 breast
cancer cells in an established mouse lung metastasis
model. We started dosing the antibody at the time whenFigure 5 Epitope binning of anti-Nectin-2 mAbs. Each column and row
mAb, respectively. The red, yellow, and white cells show a combination of
inhibition, respectively. The dendrogram shown on the left side of the mat
Lead Discovery.the colonies of MDA-MB-231 cells became visible in the
lungs. As shown in Figure 10, Y-443 suppressed the
growth of MDA-MB-231 cells in lungs in a dose-
dependent manner. The minimum effective dose of Y-443
for this experimental condition was 0.1 mg/kg.
Mechanism of action of the in vivo anti-tumor effect of Y-443
The differences in the in vitro characteristics of Y-187
and Y-443 and the similarities in anti-tumor effects onin the matrix represents an unlabeled and biotinylated anti-Nectin-2
antibodies that showed > 70%, > 50%, and < 50% competitive binding






























Figure 6 Inhibitory activity of anti-Nectin-2 mAb Y-187 on the
proliferation of OV-90 cells. OV-90 cells were cultured in the
presence of the indicated concentrations of Y-178, anti-Nectin-2
poAb, or control IgG with 1% FBS for 6 days. The percentage



































Figure 8 ADCC of anti-Nectin-2 mAbs against OV-90 cells. OV-
90 cells pre-labeled with 51Cr were incubated with anti-Nectin-2
mAbs at a ratio of 1:50 with PBMC effector cells for 4 h at 37°C,
followed by the measurement of 51Cr that was released into the
culture supernatant. Specific cell lysis was calculated as described in
Methods. The numbers in parentheses indicate the epitope bin of
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http://www.molecular-cancer.com/content/12/1/60OV-90 cells described above suggested that the anti-
tumor effects of these 2 mAbs were not dependent on
in vitro inhibitory activities against cell proliferation,
Nectin-2-Nectin-2 interaction or Nectin-2-Nectin-3
interaction, but were most likely dependent on ADCC.
To confirm this, we prepared recombinant Y-443 IgG4
antibody in which the IgG1 Fc region of Y-443 was
swapped for IgG4 Fc since IgG4 isoform is known to
have much less ADCC activity [25]. The binding activity



























































































Figure 7 Inhibitory activity of anti-Nectin-2 mAbs on Nectin-2-
Nectin-2 and Nectin-2-Nectin-3 interaction. Inhibitory activity of
anti-Nectin-2 mAbs on Nectin-2-Nectin-2 interaction and Nectin-2-
Nectin-3 interaction were measured by using an ELISA-based time-
resolved fluorescence spectroscopy assay and a Biacore assay,
respectively. The percentage inhibition of Nectin-2-Nectin-2 or























Figure 9 In vivo anti-tumor effect of anti-Nectin-2 mAbs in the
OV-90 mouse subcutaneous xenograft preventive model. OV-90
cells were subcutaneously inoculated into the flanks of nude mice.
On the same day, Y-187 or Y-443 at a dose of 15 mg/kg or vehicle
was intravenously administered on a biweekly basis to the mice. The
results are mean ± S.D. or tumor volume. **: p < 0.001 versus the





























Figure 10 In vivo anti-tumor effect of Y-443 in the established
MDA-MB-231 mouse lung metastasis model. MDA-MB-231 cells
were intravenously injected into nude mice. From day 33, various
doses of Y-443 or vehicle were intravenously administered on a
weekly basis into the mice. The results are the mean ± S.D. at day 61.
*: p < 0.025, versus vehicle group as determined by the one-tailed
Shirley-Williams test.





















Figure 11 ADCC of Y-443 and its IgG4 against MDA-MB-231
cells. MDA-MB-231 cells pre-labeled with 51Cr were incubated with
Y-443 (IgG1), Y-443 IgG4, or control human IgG at a ratio of 1:50 with
PBMC effector cells for 4 h at 37°C, followed by measurement of
51Cr that was released into the culture supernatant. Specific cell lysis
was calculated as described in Methods. The results are the mean ±
S.D. of triplicate assays.
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http://www.molecular-cancer.com/content/12/1/60the IgG1 isoform (KD = 2.9 nM and 3.0 nM, respectively).
Y-443 (IgG1) showed potent ADCC against MDA-MB-
231 cells, and the ADCC disappeared as a result of
Fc-conversion to IgG4 (Figure 11). In a mouse subcuta-
neous xenograft established model carrying the same
breast cancer cells, the tumor growth inhibitions (TGIs)
of Y-443 (IgG1) at 0.3 and 1 mg/kg were 65% and 53%,
respectively (Figure 12). In contrast, the TGIs of Y-443
IgG4 at 0.3, 1, and 3 mg/kg were 39%, 31% and 39%,
respectively. Thus, Y-443 IgG4 at 3 mg/kg showed less
anti-tumor effect than Y-443 (IgG1) at 0.3 mg/kg.
Tao et al. reported that IgG1 but not IgG4 isoform
could exert complement-dependent cytotoxicity (CDC)
as an effector function [26]. Therefore, we investigated
the contribution of CDC in the anti-tumor effect of
Y-443 (IgG1). However, as shown in Figure 13, Y-443
(IgG1) did not show CDC against MDA-MB-231 cells at
all, whereas rituximab showed marked CDC against Daudi
cells under similar conditions. These results suggest that
the in vivo anti-tumor effect of the anti-Nectin-2 mAb
was mainly attributed to ADCC.
Discussion
The over-expression of Nectin-2 in breast and ovarian
cancer tissues and various cancer cell lines at the mRNA
and protein levels (Figures 1 and 2; Tables 1 and 2) sug-
gests the potential of Nectin-2 as a target for antibody
therapeutics to treat patients that are afflicted with these
cancers. In addition, the over-expression of Nectin-2 incell lines derived from various types of cancers (Figure 3)
and in neuroblastoma, myeloid and lymphoblastic leuke-
mias, gastric cancer, and colon cancer [27-29] suggests
the possibility for the application of anti-Nectin-2 anti-
body to treat various cancer types.
Since a partial growth inhibition of OV-90 ovarian
cancer cells had been observed using anti-Nectin-2
poAb, we generated 256 Nectin-2-specific fully human
mAbs from KM mice. The mAbs were classified into 7
epitope bins by a competitive binding inhibition method
using recombinant CHO cells that over-expressed Nectin-
2 (Figure 5). In this assay format, 2 antibodies were classi-
fied into the same epitope bin if they bound to epitopes
that were close together but were not identical and could
also competitively bind to Nectin-2 due to steric hin-
drance. Therefore, the number of epitope bins for our
anti-Nectin-2 mAbs might have been underestimated.
In the Nectin-2 interaction assay, 73 out of the 78
neutralizing mAbs belonged to epitope bin V or VI (rep-
resentative data are shown in Figure 7). Interestingly,
these mAbs failed to bind to a Nectin-2 Ig1 domain
deletion mutant, whereas they retained the ability to
bind to a Nectin-2 Ig2 domain deletion mutant (data not
shown). These results demonstrate that the epitopes of
antibodies in epitope bins V and VI are located in the
Ig1 domain, which has been reported to mediate Nectin-
2-Nectin-2 and/or Nectin-2-Nectin-3 trans-binding























































Figure 12 In vivo anti-tumor effect of Y-443 IgG1 versus Y-443 IgG4 in the established MDA-MB-231 mouse subcutaneous xenograft
model. MDA-MB-231 cells were injected into SCID mice, and the mice were then treated with Y-443 IgG1 (A) or Y-443 IgG4 (B) on days 36, 43,
and 50 after cell injection (n = 5). The results are the mean ± S.D. *: p < 0.025 versus the control as determined by the one-tailed Williams test.
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http://www.molecular-cancer.com/content/12/1/60inhibit these interactions. Moreover, it is noteworthy that
the antibodies in epitope bin V inhibited Nectin-2-Nectin-2
interaction more strongly than Nectin-2-Nectin-3
interaction, whereas the antibodies in epitope bin VI
inhibited Nectin-2-Nectin-3 interaction more strongly
than Nectin-2-Nectin-2 interaction (Figure 7). These
findings suggest that the interaction sites for the het-
ero interaction and homo interaction of the Ig1 domain of
Nectin-2 are not completely identical, which may enable
Nectin-2-Nectin-2 trans-dimer and Nectin-2-Nectin-3
trans-dimer to multimerize with each other.
Anti-Nectin-2 mAbs representing each epitope bin
with similar antigen binding affinity showed varying
ADCC activities, and the mAbs in epitope bin VII dem-
onstrated the strongest ADCC (Figure 8).
As mentioned previously, we found 8 anti-Nectin-2
mAbs that showed inhibitory activities in the OV-90 cell
proliferation assay. Interestingly, 7 of them belonged

















Figure 13 CDC of Y-443 against MDA-MB-231 cells. MDA-MB-231 cells
human serum complement for 60 min at 37°C. The damaged cells were sta
described in Methods. The results are the mean ± S.D. of triplicate assays.complementarity determining region (CDR) sequence
(data not shown). The results suggest that we success-
fully screened a subset of anti-Nectin-2 mAbs that
suppressed the proliferation of OV-90 cells even though
their efficacies were not marked.
The anti-Nectin-2 mAb Y-443, representing epitope
bins VII, showed in vivo anti-tumor effects on OV-90
and MDA-MB-231 cells (Figure 9 and 10), and all the
experimental results suggested that ADCC is the main
mechanism of action of Y-443.
Conclusions
This study demonstrated the over-expression of Nectin-
2 in breast and ovarian cancer tissues and showed that
the anti-Nectin-2 human mAb Y-443 exerts an in vivo
anti-tumor effect on OV-90 and MDA-MB-231 cells via
ADCC as the main mechanism of action. Thus, Nectin-


















and Daudi cells were incubated with Y-443 or rituximab together with
ined with propidium iodide. Antibody-specific CDC was calculated as
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Plasmid construction
Nectin-2 was cloned from Marathon-Ready cDNA of
the A549 human lung cancer cell line (BD Biosciences)
into mammalian expression vectors pcDNA3.1 (Invitrogen),
pEE12.4 (Lonza Biologics), and pEF1/myc-HisA (Invitrogen)
to obtain pcDNA3.1-Nectin-2, pEE12.4-Nectin-2, and
pEF1/myc-HisA-Nectin-2, respectively. The cDNA en-
coding human IgG1 and IgG4 Fc region and mouse
IgG2a Fc region were cloned from human spleen-
derived and mouse spleen-derived Marathon-Ready
cDNA (BD Biosciences), respectively. The cDNA en-
coding Nectin-2 extracellular domain (a.a. 1–361)
fused to the human IgG1 Fc region and Nectin-3 extra-
cellular domain (a.a. 1–404) fused to the mouse IgG2a
Fc region were inserted into pcDNA3.1 to obtain
pcDNA3.1-Nectin-2-ED-hFc and pcDNA3.1-Nectin-3-
ED-mFc plasmids, respectively. Similarly, the cDNA
encoding C-terminal FLAG-tagged Nectin-2 extracel-
lular domain (a.a. 1–361) and Nectin-3 extracellular
domain (a.a. 1–404) were inserted into the pCMV-
Tag4a plasmid (Stratagene) to obtain pCMV-Tag4-
Nectin-2-ED-FLAG and pCMV-Tag4-Nectin-3-ED-FLAG
plasmids, respectively. To obtain an expression plasmid
encoding Y-443 with the human IgG4 Fc region, cDNA of
the variable regions of the heavy chain or light chain of
Y-443 were inserted into the GS expression vector pEE6.4
(Lonza Biologics) with human IgG4 Fc region cDNA or
pEE12.4, respectively. The Y-443 IgG4 expression vector
was constructed by ligation of the heavy and light chain
vector.
Cells
OV-90 and MDA-MB-231 cells were purchased from
the American Type Culture Collection (ATCC). OV-90
cells were grown in a 1:1 mixture of MCDB 105 medium
and Medium 199 containing 15% fetal bovine serum
(FBS). MDA-MB-231 cells were grown in Leibovitz’s
L-15 medium containing 10% FBS. FM3A (Health Pro-
tection Agency Culture Collections (HPACC)) cells
were grown in RPMI1640 containing 10% FBS. CHO
(Lonza Biologics) and NS0 cells (Lonza Biologics) were
cultured in DMEM containing 10% dialyzed FBS. The
other cancer cell lines for Nectin-2 expression tests
for FCM analysis were purchased from the ATCC, the
German Collection of Microorganisms and Cell Cul-
tures (DSMZ), the Japanese Collection of Research
Bioresources Cell Bank (JCRB), and HPACC, and were
cultured according to the provider’s instructions.
To obtain Nectin-2 stable transfectants, pEF1/myc-HisA-
Nectin-2 was transfected into FM3A cells by using a Gene
Pulser II (Bio-Rad). The cells were cultured in 96-well
plates with selection medium containing Geneticin (Life
Technologies). Likewise, pEE12.4/Nectin-2 was transfectedinto CHO and NS0 cells using a Gene Pulser II. The
transfected cells were cultured in 96-well plates with
selection medium containing methionine sulfoximine
and L-glutamine-free selection medium, respectively.
Single colonies grown in the selection media were
expanded and the expression level of Nectin-2 on the
cell surface was measured by FCM using anti-Nectin-2
poAb. Thus, recombinant cell lines expressing Nectin-2
(Nectin-2/FM3A, Nectin-2/CHO, and Nectin-2/NS0)
were obtained.
Recombinant protein preparation
Recombinant proteins Nectin-2-ED-FLAG and Nectin-
3-ED-FLAG were transiently expressed in FreeStyle
293 F cells (Life Technologies) by transfecting pCMV-
Tag4-Nectin-2-ED-FLAG or pCMV-Tag4-Nectin-3-
ED-FLAG using 293fectin (Life Technologies), respect-
ively. The Nectin-2-ED-FLAG and Nectin-3-ED-FLAG
proteins were then purified from the culture super-
natant by anti-FLAG antibody column chromatog-
raphy (Sigma-Aldrich) followed by a buffer exchange
with Dulbecco’s phosphate-buffered saline (D-PBS)
using an ultra-filtration system (Amicon). Similarly,
recombinant Nectin-2-ED-hFc and Nectin-3-ED-mFc
were obtained by the transfection of pcDNA3.1-
Nectin-2-ED-hFc or pcDNA3.1-Nectin-3-ED-mFc, re-
spectively. The Nectin-2-ED-hFc and Nectin-3-ED-mFc
proteins were purified from the culture supernatant with
Protein A Sepharose (GE Healthcare), followed by a buffer
exchange with D-PBS using an ultra-filtration system.
Anti-Nectin-2 poAb
Anti-Nectin-2 poAb was raised in New Zealand white
rabbits by immunizing with recombinant Nectin-2-ED-
FLAG protein emulsified with Freund’s adjuvant every
2 weeks for 3 months. The anti-Nectin-2 poAb was puri-
fied from the antiserum by affinity chromatography
using a HiTrap NHS-Activated HP column (GE Healthcare)
on which Nectin-2-ED-FLAG was immobilized. The puri-
fied antibodies were then passed through a Nectin-3-ED-
FLAG-affinity column in order to remove antibodies that
were cross-reactive to Nectin-3 or FLAG tag. The flow
through fraction was used as a Nectin-2-specific poAb.
mRNA expression analysis
Expression levels of Nectin-2 mRNA in normal tissues
and cancer tissues were quantified by analyzing Affymetrix
U_133 array data from Gene Logic. Nectin-2 mRNA level
was calculated by multiplying each expression intensity
for a given experiment (a sample hybridized onto a chip)
by a global scaling factor. The scaling factor was calcu-
lated as follows: (1) from all the non-normalized expres-
sion values in the experiment, the largest 2% and smallest
2% of the values were deleted; (2) the mean of the
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scale factor was calculated as 100/(trimmed mean). The
value of 100 used here is the standard target value used by
Gene Logic. A genechip probe 232078_at for human
Nectin-2 was used for the analysis. Primary cancer tissues
were used in the analysis as cancer tissues.
IHC
The expression level of Nectin-2 protein in tissues was
examined by IHC using paraffin-embedded normal tis-
sue sections and cancer tissue sections from cancer pa-
tients (Cybrdi). The tissue sections were deparaffinized,
blocked with goat serum (Vector Laboratories) for 20 min
at room temperature, and incubated with 1 μg/mL anti-
Nectin-2 rabbit poAb for 18 h at 4°C. After 3 washes with
D-PBS, the tissue sections were incubated with ENVI-
SION+ Rabbit/HRP (Dako) for 30 min and then devel-
oped with 3, 3′-diaminobenzidine for 3 min at room
temperature. The sections were counterstained with
hematoxylin and mounted in Permount (Fisher Scientific).
Cases with membranous staining in tumor cells were
considered positive for Nectin-2 expression. The antigen-
specificity of the positive samples was confirmed by stain-
ing without anti-Nectin-2 primary antibody.
FCM
Cancer cells were incubated with 3 μg/mL anti-Nectin-2
rabbit poAb for 1 h on ice followed by incubation with
2 μg/mL Alexa488-labeled anti-rabbit IgG (Life Tech-
nologies) for 1 h on ice. Cells were washed with D-PBS
containing 2% FBS after each antibody incubation step.
The fluorescence intensity was measured by using a
Cytomics FC 500 instrument (Beckman Coulter). The
MFI ratio of the Ab-treated sample to a control sample
was used as a measure of the cell surface expression
level of Nectin-2 in cancer cells. A control sample was
prepared by incubating cells with a rabbit IgG control
(Jackson ImmunoResearch Laboratories).
Generation of fully human anti-Nectin-2 mAbs
KM mice (10–12-weeks old, male; Kyowa Hakko Kirin)
were immunized with Nectin-2-expressing cells (Nectin-
2/NS0 or Nectin-2/FM3A), a recombinant protein of
Nectin-2 extracellular domain (Nectin-2-ED-hFc or
Nectin-2-ED-FLAG), or a combination of Nectin-2/FM3A
and the recombinant protein. For cell immunization,
Nectin-2/NS0 or Nectin-2/FM3A cells were pre-treated
with 20 μg/mL Mitomycin C (Wako) for 30 min at 37°C,
and then they were injected intraperitoneally into the mice
with Ribi adjuvant at 1 × 107 cells per mouse weekly for
7 weeks. For protein immunization, an emulsion of 50 μg
of Nectin-2-ED-hFc or Nectin-2-ED-FLAG and Freund’s
complete adjuvant (Difco) was subcutaneously injected
into the KM mice. The following immunizations wererepeated twice using the same amount of immunogens
emulsified with Freund’s incomplete adjuvant at 2-week
intervals. Two weeks after the third immunization, 10 μg
of Nectin-2-ED-hFc or Nectin-2-ED-FLAG was injected
into the tail vein as a final boost. For combination
immunization, the first immunization was conducted sub-
cutaneously with Nectin-2-ED-hFc or Nectin-2-ED-FLAG
emulsified with Freund’s complete adjuvant followed by
the second immunization with the same amount of the
proteins emulsified with Freund’s incomplete adjuvant at
2-weeks intervals. In parallel, Mitomycin C treated-
Nectin-2/FM3A cells were intraperitoneally injected
into the mice every week for 4-weeks after the first
protein immunization. Three days after the final pro-
tein immunization or 7 days after the final cell
immunization, splenocytes were collected from mice
that showed a high serum titer against Nectin-2 in a
cell ELISA using Nectin-2/CHO and they were fused
with mouse myeloma P3X63Ag8U.1 cells (ATCC)
using Polyethylene Glycol 1500 (Roche Diagnostics).
The fused cells were cultured in a HAT (hypoxanthine-
aminopterin-thymidine)-selection media to obtain hybrid-
omas. Hybridomas that secreted anti-Nectin-2 mAb
were screened in a Nectin-2/CHO cell ELISA using the
culture supernatant. After the selected hybridomas
were further sub-cloned, all of the hybridomas that
secreted Nectin-2-specific antibody were expanded in
medium containing 10% ultra-low IgG FBS (Life Tech-
nologies) on a scale of 10–50 mL. Then, each mAb
was purified from the culture supernatant using Pro-
tein A-Sepharose resin. Antibody isotypes were deter-
mined by sandwich ELISA using a plate that was
separately coated with 6 different antibodies specific to
human IgG1, IgG2, IgG3, IgG4, IgM or the kappa chain.
Epitope binning study
Anti-Nectin-2 mAbs were biotinylated by using a Biotin
Labeling Kit-NH2 (Dojindo). Nectin-2/CHO cells (3 × 103)
were pre-incubated with 5 μg/mL unlabeled anti-Nectin-2
mAb and 330 ng/mL Streptavidin-Alexa Fluor 647
(Life Technologies) in a 384-well FMAT plate (Applied
Biosystems) for 10 min at room temperature. After in-
cubation, the biotinylated anti-Nectin-2 mAb was added
to the plate at a final concentration of 100 ng/mL and the
plate was further incubated for 1 h at room temperature.
The fluorescence intensity of Alexa Fluor 647 on Nectin-
2/CHO cells was detected by using a FMAT8200 Cellular
Detection System (Applied Biosystems). The binding inhib-
ition (%) was calculated using the following formula:
Binding inhibition %ð Þ ¼ 1–A=Bð Þ  100
where A represents the total fluorescence of the added un-
labeled antibody and B represents the total fluorescence in
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was performed with the binding inhibition data by
employing Ward’s hierarchical clustering method and
using SpotFire DecisionSite for Lead Discovery (TIBCO
Software).
Cell proliferation assay
OV-90 cells were seeded at 3 × 103 cells/well in a 96-well
plate in the presence of 1% FBS and 30 μg/mL anti-
Nectin-2 poAb or mAbs and then cultured for 6 days at
37°C. Cell proliferation was measured by using Cell
Counting Kit-8 (Dojindo). The efficacy of the anti-
Nectin-2 mAbs was evaluated with various concentra-
tions of the antibodies under the same conditions. Cell
growth inhibition (%) was calculated using the following
formula:
Cell growth inhibition %ð Þ ¼ 100 ½1–Absorbance450 with Abð Þ=
Absorbance450 without Abð Þ
Nectin-2-Nectin-2 and Nectin-2-Nectin-3 interaction
inhibition assays
Nectin-2-Nectin-3 interaction inhibition was quantita-
tively assessed using a Biacore2000 (GE Healthcare). In
brief, Nectin-3-ED-mFc protein was immobilized on sen-
sor chip CM5 (GE Healthcare) by using an Amine Coup-
ling Kit (GE Healthcare). A mixture of Nectin-2-ED-hFc
at 40 μg/mL and anti-Nectin-2 mAb at 30 μg/mL was
passed through the Nectin-3-ED-mFc immobilized chip.
Nectin-2-Nectin-3 interaction inhibition was calculated as
a percentage of the decrease in the maximum response
unit compared to a human IgG control (Jackson
ImmunoResearch Laboratories).
Nectin-2-Nectin-2 interaction inhibition was measured
by using an ELISA-based time-resolved fluorescence
spectroscopy assay. Nectin-2-ED-hFc protein was conju-
gated with europium N1 ITC chelate by using a DELFIA
Eu-Labeling Kit (PerkinElmer). Unlabeled Nectin-2-ED-
hFc protein was immobilized on to a Delfia Clear Strip
Plate (PerkinElmer). After blocking with PBS containing
2% bovine serum albumin, the Eu-labeled Nectin-2-ED-
hFc and anti-Nectin-2 mAb were simultaneously added
at final concentrations of 3.2 μg/mL and 30 μg/mL,
respectively, followed by incubation for 1.5 h at room
temperature. After washing with D-PBS containing
0.05% Tween20, Enhancement Solution (PerkinElmer)
was added to each well. The fluorescence intensity was
measured at 615 nm with an excitation wavelength of
340 nm and a delayed time of 400 μs by using an
ARVO1420 Multilabel Counter (PerkinElmer). Nectin-
2-Nectin-2 interaction inhibition was calculated as a
percentage of the decrease in the fluorescence signal
compared to a human IgG control.ADCC assay
Human peripheral blood mononuclear cells (PBMC)
from AllCells were cultured in RPMI1640 medium
containing 10% FBS, 0.1 nM human IL-2 (DIACLONE
Research), and 55 μM 2-mercaptoethanol for 24 h.
PBMC were incubated with 51Cr-labeled OV-90 cells or
51Cr-labeled MDA-MB-231 cells at a ratio of 50:1 in the
presence of anti-Nectin-2 mAb for 4 h at 37°C. After in-
cubation, the radioactivity of 51Cr that had been released
into the culture medium from the target cells was mea-
sured by using an AccuFLEX γ 7000 (Aloka). Specific
lysis by anti-Nectin-2 mAb was calculated using the
following formula:
Specific lysis %ð Þ ¼ 100 A–Bð Þ= C–Bð Þ
where A represents the radioactivity of the test super-
natant, B represents the radioactivity of the target cells
alone, and C represents the radioactivity of the max-
imum 51Cr release from the target cells that were lysed
with 1% Triton X-100.
CDC assay
MDA-MB-231 cells (5 × 103) were incubated with 10-
fold diluted human serum complement (Quidel) and
various concentrations of Y-443 in a black wall/transpar-
ent bottom 96-well plate (BD Biosciences) for 60 min at
37°C. The cells were stained with 10 μM propidium iod-
ide (PI), and the PI-positive cells (CDC-damaged cells)
were detected using an Acumen ex3 instrument (TTP
Labtech). As a positive control, rituximab (Roche) was
used in combination with Daudi cells (ATCC). CDC
activity was calculated using the following formula:
CDC activity %ð Þ ¼ 100 A–Bð Þ= C–Bð Þ
where A represents the number of PI-positive cells in
the presence of mAb and human serum, B represents
that in the absence of mAb, and C represents the num-
ber of PI-positive cells that were incubated with 0.1%
Triton X-100.
Preparation of anti-Nectin-2 mAbs for in vivo study
The hybridomas that produced Y-187 and Y-443 were
cultured in Daigo’s T medium (Nihon Pharmaceutical)
containing 10% Ultra Low IgG FBS (Life Technologies).
The culture supernatant was filtered, concentrated, and
then purified with a Protein A-column. The antibody
fraction was separated on a Superdex 200 26/60 column
(GE Healthcare) to obtain the monomer fraction and
endotoxins were removed by using an ActiClean Etox
column (Sterogene). The recombinant IgG4 form of
Y-443 was prepared as follows. CHOK1SV cells (Lonza
Biologics) were maintained in CD-CHO medium (Life
Technologies) containing 6 mM L-glutamine. Linearized
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CHOK1SV cells with a Gene Pulser II. The cells were
seeded into 96-well plates at 37°C in a humidified 8%
CO2. After 1 day of culturing, methionine sulfoximine
(MSX) was added at a final concentration of 25 μM.
After selection of the culture, a recombinant CHOK1SV
clone that produced high levels of Y-443 IgG4 was
selected and the cells were expanded into T75 flasks in
serum-free CD-CHO medium containing 25 μM MSX
and then adapted into a suspension culture. Y-443 IgG4
was purified from the supernatant of a 1 L fed-batch
culture by chromatography with Protein A Sepharose FF
(GE Healthcare), followed by Superdex200 26/60.
In vivo study
For the OV-90 subcutaneous mouse xenograft model,
8 × 106 OV-90 cells were subcutaneously inoculated into
a flank of BALB/cAJcl-nu/nu mice (6 weeks old, females)
from CLEA Japan. The mice were randomly grouped (n =
13–17). Vehicle (D-PBS), Y-187, or Y-443 (15 mg/kg) was
intravenously injected twice weekly for 5 weeks from the
day of the cancer cell inoculation. Tumor diameters were
measured with a caliper twice weekly and approximate
tumor volumes were calculated as 0.5 × length × (width)2
during the treatment period to monitor tumor growth.
The TGI was calculated by the following formula:
TGI ¼ 100 1–A=Bð Þ
where A is the average tumor volume for the Ab-treated
group and B is the average tumor volume for the vehicle
group.
The difference in the average tumor volume between
the Ab-treated groups and the vehicle group was ana-
lyzed using the Steel test.
For the MDA-MB-231 subcutaneous xenograft model,
3 × 106 MDA-MB-231 cells were subcutaneously inocu-
lated with Matrigel (Becton Dickinson) into BALB/
cAJcl-nu/nu mice (6 weeks old, female) as described
above. The mice were grouped 36 days after the inocula-
tion when the average sizes of the tumors reached ap-
proximately 200 mm3 and then vehicle (D-PBS), Y-443
(0.3 and 1 mg/kg), or its IgG4 form antibody (0.3, 1, and
3 mg/kg) was intravenously injected once per week for
3 weeks. The tumor volumes were measured and the
TGI for each treatment group was determined at day 57
as described above. The difference in the average tumor
volume between the Ab-treated groups and the vehicle
group was analyzed using Williams test.
The MDA-MB-231 lung metastasis model was carried
out as follows. Briefly, 100 μL of 1 × 106 cultured MDA-
MB-231 cancer cell suspension in Hank’s buffered salt
solution was intravenously injected into the tail vein of
SCID mice (5–6 weeks old). The mice were randomlygrouped (n = 5) 33 days after the inoculation and were
treated with vehicle (D-PBS) or Y-443 (0.001, 0.01, 0.1,
1, or 10 mg/kg) weekly on days 33, 40, 47, and 54. On
day 61, the mice were sacrificed to excise the lungs, and
0.2% Evans blue dye was injected intratracheally to
visualize their tumor colonies. The lungs were subse-
quently fixed with a mixture of picric acid, 10% neutral
buffered formalin, and acetic acid (15:5:1), and the num-
ber of colonies on the diaphragmatic surface of the lungs
was counted macroscopically in a blind manner. The dif-
ference between the colony numbers of the Ab-treated
group and the vehicle group was analyzed using the
one-tailed Shirley-Williams test.
All of the animal studies including immunization were
carried out in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The proto-
col was approved by the Committee on the Ethics of
Animal Experiments of Takeda Pharmaceutical Com-
pany Ltd. (Permit Numbers: 2802, 2701, and E1-0311).
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